Iron Deficiency Anemia - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Iron Deficiency Anemia - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Iron Deficiency Anemia - Pipeline Review, H2 2015', provides an overview of the Iron Deficiency Anemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Iron Deficiency Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Iron Deficiency Anemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Iron Deficiency Anemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Iron Deficiency Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Iron Deficiency Anemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Iron Deficiency Anemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Iron Deficiency Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Iron Deficiency Anemia Overview 6
Therapeutics Development 7
Pipeline Products for Iron Deficiency Anemia - Overview 7
Pipeline Products for Iron Deficiency Anemia - Comparative Analysis 8
Iron Deficiency Anemia - Therapeutics under Development by Companies 9
Iron Deficiency Anemia - Therapeutics under Investigation by Universities/Institutes 10
Iron Deficiency Anemia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Iron Deficiency Anemia - Products under Development by Companies 14
Iron Deficiency Anemia - Products under Investigation by Universities/Institutes 15
Iron Deficiency Anemia - Companies Involved in Therapeutics Development 16
Panion & Bf Biotech Inc 16
Rockwell Medical, Inc. 17
Vifor Pharma AG 18
Iron Deficiency Anemia - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
ferric carboxymaltose - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ferric citrate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ferric maltol - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ferric pyrophosphate citrate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
NSC-8679 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Proteins to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
VIT-91 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Iron Deficiency Anemia - Recent Pipeline Updates 39
Iron Deficiency Anemia - Dormant Projects 53
Iron Deficiency Anemia - Product Development Milestones 54
Featured News & Press Releases 54
May 12, 2015: Rockwell Medical Announces Triferic Clinical Data Selected for Four Presentations at the 52nd ERA-EDTA Congress May 28-31, 2015 in London, UK 54
May 05, 2015: Rockwell Medical to Present at Bank of America Merrill Lynch 2015 Health Care Conference 54
Mar 26, 2015: Rockwell Medical Announces Triferic Clinical Data Selected for Four Poster Presentations at National Kidney Foundation Spring Clinical Meetings March 26-29, 2015 in Dallas, Texas 54
Jan 26, 2015: U.S. FDA Approves Rockwell's Triferic for Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients 55
Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch 56
Jan 09, 2015: Shield Therapeutics announces the publication of the AEGIS Feraccru Phase 3 pivotal trial manuscript in the Inflammatory Bowel Disease Journal 57
Jan 07, 2015: Rockwell Medical Announces Two Triferic Abstracts to be Presented at Annual Dialysis Conference Jan. 31 - Feb. 3, 2015 in New Orleans, Louisiana 57
Dec 15, 2014: American Regent's Injectafer (ferric carboxymaltose injection) Assigned J Code by Centers for Medicare & Medicaid Services 58
Dec 08, 2014: American Regent Announces Clinical Data Presentations at ASH 2014 59
Nov 11, 2014: Three clinical Presentations Highlight Novel Iron Replacement Drug Triferic at ASN 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for Iron Deficiency Anemia, H2 2015 7
Number of Products under Development for Iron Deficiency Anemia - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Late Stage Development, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Iron Deficiency Anemia - Pipeline by Panion & Bf Biotech Inc, H2 2015 16
Iron Deficiency Anemia - Pipeline by Rockwell Medical, Inc., H2 2015 17
Iron Deficiency Anemia - Pipeline by Vifor Pharma AG, H2 2015 18
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Stage and Target, H2 2015 21
Number of Products by Stage and Mechanism of Action, H2 2015 23
Number of Products by Stage and Route of Administration, H2 2015 25
Number of Products by Stage and Molecule Type, H2 2015 27
Iron Deficiency Anemia Therapeutics - Recent Pipeline Updates, H2 2015 39
Iron Deficiency Anemia - Dormant Projects, H2 2015 53